Jefferies Reaffirms 'Buy' Rating on LivaNova PLC (LIVN) with $79 PT

Offering strong upside potential, LivaNova PLC (NASDAQ:LIVN) earns a spot on our list of the 10 Most Undervalued Foreign Stocks to Buy According to Analysts.

On June 5, 2025, LivaNova PLC (NASDAQ:LIVN) reported the completion of its landmark CORE-VNS study. More than 800 real-world patients with drug-resistant epilepsy were tracked under this study. The results were positive. Significant and lasting seizure reductions were noted, confirming VNS Therapy’s effectiveness in both children and adults. In some cases, a 100% reduction was noted.

In response to the positive results, Jefferies reaffirmed its ‘Buy’ rating the following day, with a $79 price target. The analyst attributed it to strong product cycles, including upgrades to the company’s Essenz platform and growing oxygenator market share. Previously, in May, Wolfe Research also upgraded the stock to ‘Outperform’, highlighting the improved legal clarity in Italy and high growth potential in its depression and sleep apnea treatment pipelines.

Through its Cardiopulmonary and Neuromodulation segments, LivaNova PLC (NASDAQ:LIVN) develops products and therapies for neurological and cardiac patients worldwide. It remains on our list of the most undervalued stocks.

While we acknowledge the potential of LIVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Most Undervalued Cloud Stocks Under $10 According to Hedge Funds and 11 Best Mineral Stocks to Buy According to Hedge Funds.

Disclosure: None.